泰的T1 -晚打破抽象皮质类固醇优化在严重哮喘使用复合生物标志物来调整剂量和症状/风险算法JF -欧洲呼吸杂志乔——欧元和J - 10.1183/13993003.国会- 2020.4618六世- 56 - 64 SP - 4618 AU -蒂姆Hardman AU -莱姆·希尼盟-约翰·巴斯比非盟-凯瑟琳韩瑞提非盟-姆也有非盟-阿什利丘鹬盟萨曼莎沃克AU -约瑟夫炎亚纶盟-大卫(AU -彼得·布拉德AU -克里斯托弗Brightling盟Rehka乔杜里盟——道格拉斯·科文AU -罗伯·尼文——斯蒂芬·福勒盟蒂姆·哈里森AU -彼得•霍沃斯盟吉姆Lordan AU -阿德尔曼苏尔AU -安德鲁Menzies-Gow AU -道格拉斯·罗宾逊Y1 - 2020/09/07 UR - //www.qdcxjkg.com/content/56/suppl_64/4618.abstract N2 -简介:增加皮质类固醇(CS)控制哮喘症状和发作有潜力不高,难以down-titrate CS剂量。目标和目标:我们测试是否T2 biomarker-based策略(BS)指导降低CS(保理分式呼出一氧化氮(FeNO),血液嗜酸性粒细胞,血清periostin)和症状控制会看到更少的加重和更好的哮喘控制和肺功能。方法:随机(4:1 / BS:控制),单盲平行组试验中,患者(pts)患有严重哮喘和FeNO & lt; 45磅的有组织特定指令CS调整每8周内。主要结果是分的比例实现CS Wk48减少。二次结果包括恶化率、肺功能和哮喘控制。结果:意向处理人口(240 BS和61控制分),BS的比例分在CS低剂量Wk48在控件(28.4%比18.5%或调整:1.71;95% ci 0.80, 3.63;p = 0.165)。在每个协议(PP)人口(n = 121),更分在Wk48 CS剂量较低的废话和对照组(30.7%比5.0% (OR: 11.48;95% ci 1.35, 97.83;p = 0.026)。未能遵循治疗建议ITT和PP人口差异的主要原因。 There was no difference in secondary outcomes between study arms.Conclusion: Biomarker based CS adjustment did not result in a greater proportion of pts reducing CS vs. control, probably because many pts did not follow treatment advice. The biomarker strategy seemed beneficial in pts where symptoms and T2 biomarker profile were discordant.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 4618.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -